Onco-Innovations Limited (NEO:ONCO)

Onco-Innovations Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023
Net Income	-8.49	-0.39	-0
Asset Writedown & Restructuring Costs	3.66	-	-
Stock-Based Compensation	1.73	-	-
Other Operating Activities	0.16	-	-
Change in Accounts Receivable	-0.05	-	-
Change in Accounts Payable	0.14	0.39	0
Change in Other Net Operating Assets	-1	-	-
Operating Cash Flow	-3.86	-0.01	-0
Cash Acquisitions	0.1	-	-
Investing Cash Flow	0.1	-	-
Long-Term Debt Repaid	-0.02	-	-
Net Debt Issued (Repaid)	-0.02	-	-
Issuance of Common Stock	4.56	1.35	0.02
Other Financing Activities	-0.12	-	-
Financing Cash Flow	4.42	1.35	0.02
Net Cash Flow	0.66	1.34	0.02
Levered Free Cash Flow	-1.01	-	-
Unlevered Free Cash Flow	-1.01	-	-
Change in Working Capital	-0.91	0.39	0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.